Successful liver transplantation following medical management of portopulmonary hypertension: A single-center series

American Journal of Transplantation

Volumn 6, Issue 9, 2006, Pages 2177-2182

  Sussman, N ^a   Kaza, V ^a   Barshes, N ^a   Stribling, R ^a   Goss, J ^a   O'Mahony, C ^a   Zhang, E ^a   Vierling, J ^a   Frost, A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Liver cirrhosis; Liver transplantation; Pulmonary hypertension

Indexed keywords

BOSENTAN; LACTULOSE; PROSTACYCLIN; SILDENAFIL; VASODILATOR AGENT;

ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REGIMEN; FEMALE; FLUSHING; HEART OUTPUT; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; NAUSEA; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; SURVIVAL TIME; TRANSPLANTATION TOLERANCE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; EPOPROSTENOL; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREOPERATIVE CARE; TIME FACTORS;

EID: 33746909482     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01432.x     Document Type: Article

References (28)

1. Mantz FA, Jr. Craige E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. AMA Arch Pathol 1951; 52: 91-97.
2. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003; 52: 1355-1362.
3. Kawut SM, Taichman DB, Ahya VN et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005; 11: 1107-1111.
4. Krowka MJ. Portopulmonary hypertension and the issue of survival. Liver Transpl 2005; 11: 1026-1027.
5. Krowka MJ. Editorial: Pulmonary hypertension, (high) risk of orthotopic liver transplantation, and some lessons from "primary" pulmonary hypertension. Liver Transpl 2002; 8: 389-390.
6. Starkel P, Vera A, Gunson B, Mutimer D. Outcome of liver transplantation for patients with pulmonary hypertension. Liver Transpl 2002; 8: 382-388.
7. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6: 443-450.
8. De Wolf AM, Scott V, Bjerke R et al. Hemodynamic effects of inhaled nitric oxide in four patients with severe liver disease and pulmonary hypertension. Liver Transpl Surg 1997; 3: 594-597.
9. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997; 3: 494-500.
10. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series. Ann Intern Med 1999; 130: 740-743.
11. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30: 641-648.
12. Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: A safe and effective therapy? Gastroenterology 2005; 128: 164-168.
13. Levy MT, Torzillo P, Bookallil M, Sheil AG, McCaughan GW. Case report: Delayed resolution of severe pulmonary hypertension after isolated liver transplantation in a patient with cirrhosis. J Gastroenterol Hepatol 1996; 11: 734-737.
14. Schott R, Chaouat A, Launoy A, Pottecher T, Weitzenblum E. Improvement of pulmonary hypertension after liver transplantation. Chest 1999; 115: 1748-1749.
15. Losay J, Piot D, Bougaran J et al. Early liver transplantation is crucial in children with liver disease and pulmonary artery hypertension. J Hepatol 1998; 28: 337-342.
16. Mandell MS. Hepatopulmonary syndrome and portopulmonary hypertension in the model for end-stage liver disease (MELD) era. Liver Transpl 2004; 10(10 Suppl 2): S54-S58.
17. Chua R, Keogh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 2005; 24: 498-500.
18. Clift PF, Townend JN, Bramhall S, Isaac JL. Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan. Transplantation 2004; 77: 1774-1775.
19. Laving A, Khanna A, Rubin L, Ing F, Dohil R, Lavine JE. Successful liver transplantation in a child with severe portopulmonary hypertension treated with epoprostenol. J Pediatr Gastroenterol Nutr 2005; 41: 466-468.
20. Minder S, Fischler M, Muellhaupt B et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 2004; 24: 703-707.
21. Plotkin JS, Kuo PC, Rubin LJ et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998; 65: 457-459.
22. Tan HP, Markowitz JS, Montgomery RA et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transpl 2001; 7: 745-749.
23. Molnar C, Alber H, Colleselli D, Vogel W, Kahler CM. Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis. Wien Klin Wochenschr 2004; 116: 627-630.
24. Suleman N, Frost AE. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest 2004; 126: 808-815.
25. Wiesner R, Edwards E, Freeman R et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96.
26. Hoeper MM, Halank M, Marx C et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005; 25: 502-508.
27. Kahler CM, Graziadei I, Wiedermann CJ, Kneussl MP, Vogel W. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. Wien Klin Wochenschr 2000; 112: 637-640.
28. Kuo PC, Plotkin JS, Johnson LB et al. Distinctive clinical features of portopulmonary hypertension. Chest 1997; 112: 980-986.